ArticleJournal of biomedical science2026
Thrombomodulin facilitates melanoma progression via FAK- and ezrin-mediated phenotypic plasticity.
Article in Journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer cell plasticity enables dynamic transitions between cellular states, contributing to tumor progression and the acquisition of phenotypic traits such as vascular mimicry (VM), which promotes malignancy and resistance to anti-angiogenic therapies. Thrombomodulin (TM), a type I transmembrane glycoprotein known for initiating sprouting angiogenesis, has been implicated in tumor vascularization. However, its role in melanoma progression and VM remains poorly characterized.
methodsTM expression was evaluated in human cutaneous melanoma biopsies and an endothelial-melanoma co-culture system. Functional assays were conducted to assess the impact of TM knockdown and overexpression on cell adhesion and VM formation. Domain-specific contributions of TM were investigated using constructs targeting its lectin-like domain and ezrin-binding motif. Mechanistic studies involved pharmacological inhibition of focal adhesion kinase (FAK) and siRNA-mediated silencing of ezrin. Therapeutic potential was assessed using a soluble TM lectin domain in both in vitro and in vivo melanoma models.
resultsTM was expressed in both angiogenic and non-angiogenic vessels within melanoma tissues and co-culture systems. TM knockdown impaired cell adhesion and suppressed VM formation, while TM overexpression in TM-null melanoma cells enhanced cellular plasticity via its lectin-like domain and ezrin-binding motif. Inhibition of FAK or silencing of ezrin reversed the TM-induced phenotypic switch. Treatment with a soluble TM lectin domain reduced cancer cell plasticity in vitro and significantly inhibited melanoma tumor growth and metastasis in vivo.
conclusionsTM promotes melanoma cell plasticity and VM through FAK- and ezrin-dependent pathways. These findings position TM as a key regulator of tumor progression and suggest that targeting TM may offer a novel therapeutic strategy to disrupt cancer cell plasticity and suppress melanoma growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.